Head-To-Head Analysis: Palvella Therapeutics (PVLA) versus Its Peers

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Palvella Therapeutics to similar businesses based on the strength of its analyst recommendations, institutional ownership, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Palvella Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8140	21793	49588	1308	2.55

Palvella Therapeutics currently has a consensus price target of $40.33, suggesting a potential upside of 109.85%. As a group, “Pharmaceutical preparations” companies have a potential upside of 239.80%. Given Palvella Therapeutics’ rivals higher possible upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Palvella Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.59
Palvella Therapeutics Competitors	$1.84 billion	$140.04 million	-7.60

Palvella Therapeutics’ rivals have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Palvella Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ rivals have a beta of 3.67, indicating that their average share price is 267% more volatile than the S&P 500.

Profitability

This table compares Palvella Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-236.05%	-32.89%

Summary

Palvella Therapeutics rivals beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.